论文部分内容阅读
卵巢癌在女性生殖器癌中发生率占第二位,但其死亡率居妇科恶性肿瘤的首位。这是由于卵巢位置隐匿,早期诊断较为困难。术后复发率高及长期化疗使癌细胞产生耐药性等。近年来,CA_(125)在卵巢癌的诊断、疗效监测等显示出可喜的应用前景。本文就这方面的一些进展作一综述。 1 CA_(125)的特点自80年代Bast等用卵巢癌细胞株免疫小鼠,获得单克隆抗体OC_(125)后,OC_(125)与CA_(125)可发生特异性结合。最近Llogd等用一种新的单抗(VK-8)分离了CA_(125),发现CA_(125)为一种大分子糖蛋白,主要含半乳酸、N-乙酰氨基葡萄糖和
Ovarian cancer in female genital cancer in the second rate, but the mortality rate ranks first in gynecological malignancies. This is due to the hidden position of the ovary, early diagnosis is more difficult. Postoperative recurrence rate and long-term chemotherapy to cancer drug resistance. In recent years, CA_ (125) in the diagnosis of ovarian cancer, efficacy monitoring showed a promising application. This article reviews some of the advances in this area. 1 Characteristics of CA 125 Since mice were immunized with Ovarian cancer cell lines such as Bast in the 1980s, OC 125 and CA125 could specifically bind to OC 125 after the monoclonal antibody OC 125 was obtained. Recently, Llogd et al. (CA) have isolated CA 125 with a new monoclonal antibody (VK-8) and found that CA 125 is a macromolecule glycoprotein containing mainly lactic acid, N-acetylglucosamine and